Aiforia Technologies

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Welcome to follow Life Science Night on Tuesday, December 9 at 3:30 pm EET on inderesTV.

Aiforia's implemented cost savings will help manage its financing needs in the coming years while the turnaround of a strong customer base into accelerating revenue growth will take time.

The company intends to ensure the achievement of its mid-term strategic goals through adjustment measures, which, in our view, means turning the business profitable by 2027.

Aiforia will at least challenge and potentially replace its competitor IBEX's solutions in the customer relationship.

This is the first completed deployment of the framework agreement Aiforia announced last year. The release supports our current view that the transition of the company's key, already won, customer accounts to a clear volume phase would take place in 2026-2028, and thus does not cause pressure to change our forecasts.

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

Through the collaboration, Siemens Healthineers will begin offering Aiforia's AI-powered solutions as part of its digital pathology portfolio to its customers in Europe.

The new Aiforia® Lymph Node Metastasis AI model is intended for the detection and quantification of breast cancer, melanoma, and colorectal cancer metastases in lymph nodes. T

Aiforia's strategy is to build a broad customer base of clinical pathology laboratories, including through partnerships, and this announcement indicates that the company is continuing along this path.